Skip to main content

Table 1 Baseline clinical features and demographic features by R+ group as defined at month 12

From: How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose

 

R+ ≤ 100 mg (n = 38)

R+  101–200 mg (n = 46)

R+ > 200 mg (n = 48)

P value

Age, yearsa

61.2 (13.3)

64.1 (9.8)

55.1 (11.6)

0.001

Male, n (%)

32 (84.2)

40 (87.0)

46 (95.8)

0.18

NZ European, n (%)

20 (52.6)

25 (54.3)

16 (33.3)

0.08

Duration of gout years, median (range)

15.2 (1.2–40.4)

18.9 (0.16–49.5)

15.7 (0.37–47.4)

0.49

Baseline serum urate mg/dla

6.6 (1.6)

6.6 (1.0)

7.6 (1.5)

<0.001

CrCl ml/mina

65.0 (29.4)

56.7 (19.4)

65.5 (27.9)

0.19

Weight kga, mean (SD)

99.2 (21.6)

104.3 (21.4)

114.3 (20.6)

0.004

Body mass index, kg/m2a

32.2 (6.3)

35.2 (7.9)

36.6 (7.3)

0.23

Baseline allopurinol dosea

250 (103)

248 (67)

316 (123)

0.002

Baseline oxypurinol concentrations, μmol/la

87.1 (42.0)

96.9 (47.9)

90.9 (56.8)

0.66

Co-existing conditions, n (%)

 Obesityb

20 (52.6)

35 (76.1)

41 (85.4)

0.003

 Cardiovascular diseasec

12 (31.6)

21 (45.7)

18 (37.5)

0.41

 Diabetes mellitus

11 (28.9)

16 (34.8)

16 (33.3)

0.84

 Hypertension

27 (71.1)

36 (78.3)

31 (64.6)

0.34

 Hyperlipidemia

25 (65.8)

25 (54.3)

25 (52.1)

0.41

Diuretic, n (%)

12 (31.6)

22 (47.8)

18 (37.5)

0.30

  1. R+ amount of allopurinol (milligrams) above creatinine clearance-based dose, CrCL creatinine clearance
  2. aMean (SD)
  3. bObesity defined as body mass index ≥ 30 kg/m2
  4. cCVD defined as ischemic heart disease, heart failure or peripheral vascular disease